Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | GALR3 | O60755 | 1/20 | 0.82 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.82 |
| ▸ | ADK | P55263 | 12/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | STAT6 | P42226 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sangivamycin SCHEMBL6731962 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL10262607 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL2786660 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL29897938 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL15107357 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL12284269 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL13065171 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL14227089 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL195540 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL20141962 | 0.99 | NPC1 (0.80) | NPC1GALR3S1PR4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| US-20230210848-A1 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-07-06 | — | — | US | claimed |
| EP-4144353-A1 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | FUJIFILM Toyama Chemical Co., Ltd. (JP) | 2023-03-08 | — | — | EP | claimed |
| EP-4100019-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | Oyagen Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| WO-2026089014-A1 | PREVENTIVE OR THERAPEUTIC AGENT AGAINST LIVESTOCK INFECTIOUS DISEASE CAUSED BY FOOT-AND-MOUTH DISEASE VIRUS | 国立研究開発法人農業・食品産業技術総合研究機構 | 2026-04-30 | — | — | WO | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| US-20250243178-A1 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-07-31 | — | — | US | disclosed |
| US-12281093-B2 | 3-(1,2,3,6-tetrahydropyridin-2-YL) pyridine glutarate or a pharmaceutically acceptable solvate thereof | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-04-22 | — | — | US | disclosed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | disclosed |
| US-20230210848-A1 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| EP-4144353-A1 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | FUJIFILM Toyama Chemical Co., Ltd. (JP) | 2023-03-08 | — | — | EP | disclosed |
| EP-4100019-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | Oyagen Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | disclosed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114641299-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | NPC1 39/4885GALR3 1485/4885S1PR4 2484/4885 |
| US-20230210848-A1 | CORONAVIRUS INFECTION THERAPEUTIC AGENT FORMED THROUGH COMBINATION OF PYRAZINE DERIVATIVE AND ANOTHER CORONAVIRUS INFECTION THERAPEUTIC DRUG | ACE2, ACE, SARS1 | NPC1 1756/4885GALR3 3373/4885S1PR4 1908/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | NPC1 25/4885GALR3 1362/4885S1PR4 2393/4885 |
| US-12281093-B2 | 3-(1,2,3,6-tetrahydropyridin-2-YL) pyridine glutarate or a pharmaceutically acceptable solvate thereof | ADH1A, GRHPR, GLS2 | NPC1 2680/4885GALR3 830/4885S1PR4 1673/4885 |
| US-20250243178-A1 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | GLS2, ADH1A, GRHPR | NPC1 2294/4885GALR3 806/4885S1PR4 1626/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | NPC1 22/4885GALR3 3574/4885S1PR4 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.